Alaunos Therapeutics, INC. (TCRT) — 8-K Filings

8-K Filings (23)

• 8-K Filing — Dec 23, 2025
• Alaunos Therapeutics Files 8-K — Aug 20, 2025 Risk: low
  Alaunos Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting an event on August 19, 2025. The filing is categorized under 'Other Events' and does not s
• Alaunos Therapeutics Reports Board and Officer Changes — Jul 22, 2025 Risk: medium
  Alaunos Therapeutics, Inc. announced on July 16, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officers
• Alaunos Therapeutics Announces Board and Officer Changes — Jul 17, 2025 Risk: medium
  Alaunos Therapeutics, Inc. announced on July 15, 2025, changes related to its board of directors and officers, including the departure of certain individuals an
• Alaunos Therapeutics Files 8-K on Security Holder Matters — Jul 10, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed an 8-K on July 10, 2025, reporting events as of July 3, 2025. The filing indicates material modifications to the rights of secu
• Alaunos Therapeutics Faces Delisting Concerns — Jul 2, 2025 Risk: high
  Alaunos Therapeutics, Inc. filed an 8-K on July 2, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company also disclo
• Alaunos Therapeutics Reports Material Definitive Agreement & Equity Sales — Jun 26, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed an 8-K on June 26, 2025, reporting on several key events as of June 24, 2025. These include entering into a material definitive
• Alaunos Therapeutics Files 8-K on Key Agreements — Jun 10, 2025 Risk: medium
  On June 9, 2025, Alaunos Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The compa
• Alaunos Therapeutics Files 8-K on Agreements and Equity Sales — May 23, 2025 Risk: medium
  Alaunos Therapeutics, Inc. filed an 8-K on May 23, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and financial st
• Alaunos Therapeutics Reports Board and Executive Changes — Apr 18, 2025 Risk: medium
  Alaunos Therapeutics, Inc. announced on April 15, 2025, changes in its board of directors and executive compensation. Specifically, the company reported the dep
• Alaunos Therapeutics Appoints New Chief Medical Officer — Apr 15, 2025 Risk: medium
  Alaunos Therapeutics, Inc. announced on April 15, 2025, that its Board of Directors appointed Dr. S. Robin Cohen as Chief Medical Officer, effective April 13, 2
• Alaunos Therapeutics Files 8-K with Key Corporate Updates — Apr 14, 2025 Risk: medium
  On April 11, 2025, Alaunos Therapeutics, Inc. filed an 8-K detailing several material events. These include the entry into and termination of material definitiv
• Alaunos Therapeutics Faces Delisting Concerns — Apr 11, 2025 Risk: high
  Alaunos Therapeutics, Inc. filed an 8-K on April 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, formerly
• Alaunos Therapeutics Terminates Material Agreement — Oct 10, 2024 Risk: medium
  Alaunos Therapeutics, Inc. announced on October 4, 2024, the termination of a material definitive agreement. The company also reported on its results of operati
• NuScale Power to Acquire Alaunos Therapeutics — Jul 16, 2024 Risk: medium
  Alaunos Therapeutics, Inc. announced on July 16, 2024, that it has entered into a definitive agreement to be acquired by NuScale Power Corporation. The transact
• Alaunos Therapeutics to be acquired by 3D Medicines for $100M — Jun 21, 2024 Risk: medium
  Alaunos Therapeutics, Inc. announced on June 19, 2024, that it has entered into a definitive agreement to be acquired by 3D Medicines Inc. for approximately $10
• Alaunos Therapeutics Files 8-K: Corporate Changes and Shareholder Votes — Jun 12, 2024 Risk: medium
  On June 6, 2024, Alaunos Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced a significant amendment to its certificate o
• Alaunos Therapeutics Reports Executive Changes and Compensation Updates — Feb 22, 2024 Risk: medium
  Alaunos Therapeutics, Inc. filed an 8-K on February 22, 2024, reporting events from February 15, 2024. The filing pertains to the departure or election of direc
• Alaunos Therapeutics Files 8-K on Feb 16 Event — Feb 20, 2024 Risk: low
  Alaunos Therapeutics, Inc. filed an 8-K on February 20, 2024, reporting an event that occurred on February 16, 2024. The filing indicates a current report pursu
• Alaunos Therapeutics Amends Charter Documents — Feb 1, 2024
  Alaunos Therapeutics, Inc. (TCRT) filed an 8-K on February 1, 2024, reporting an event on January 31, 2024, related to amendments to its Articles of Incorporati
• Alaunos Therapeutics Files 8-K, Confirms Nasdaq Listing — Jan 29, 2024
  Alaunos Therapeutics, Inc. (TCRT) filed an 8-K on January 29, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates a ro
• Alaunos Therapeutics Files Standard 8-K; No Major Changes Reported — Jan 22, 2024
  Alaunos Therapeutics, Inc. filed an 8-K on January 22, 2024, reporting an event that occurred on January 20, 2024. This filing is a standard 'Current Report' an
• Alaunos Therapeutics Reports Executive Changes & Compensation on Dec 29 — Jan 2, 2024
  Alaunos Therapeutics, Inc. filed an 8-K on January 2, 2024, reporting an event that occurred on December 29, 2023. The filing indicates a 'Departure of Director

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX